肾癌十年回顾：发现、治疗与机遇
Decade in review-kidney cancer: discoveries, therapies and opportunities.
作者信息
Linehan W Marston, Ricketts Christopher J
机构信息
Urologic Oncology Branch, National Cancer Institute, 10 Center Drive, MSC 1107, CRC Room 1W-5940, Bethesda, MD 20892-1107, USA.
出版信息
Nat Rev Urol. 2014 Nov;11(11):614-6. doi: 10.1038/nrurol.2014.262. Epub 2014 Oct 7.
Abstract
Advances in kidney cancer have occurred over the past decade, including the discovery of mutations in chromatin remodeling genes and genomic heterogeneity in clear cell renal cell carcinoma (ccRCC), altered metabolic patterns in ccRCC and papillary renal cell carcinoma and the approval of drugs for patients with ccRCC.
摘要
在过去十年中，肾癌研究取得了进展，包括在染色质重塑基因中发现突变以及在透明细胞肾细胞癌（ccRCC）中发现基因组异质性，ccRCC和乳头状肾细胞癌中代谢模式的改变，以及ccRCC患者药物的获批。
相似文献
1
Decade in review-kidney cancer: discoveries, therapies and opportunities.
Nat Rev Urol. 2014 Nov;11(11):614-6. doi: 10.1038/nrurol.2014.262. Epub 2014 Oct 7.
2
Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy.
Sci China Life Sci. 2017 Jan;60(1):91-93. doi: 10.1007/s11427-016-0297-2. Epub 2016 Nov 23.
3
Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.
J Natl Compr Canc Netw. 2016 Jul;14(7):925-7. doi: 10.6004/jnccn.2016.0095.
4
What's new in renal cell carcinoma.
Bull Am Coll Surg. 2012 Aug;97(8):65-6.
5
[Targeted therapy for renal cell carcinoma].
Nihon Jinzo Gakkai Shi. 2016;58(4):568-72.
6
Targeted therapies: another option for metastatic RCC.
Nat Rev Clin Oncol. 2013 Nov;10(11):607. doi: 10.1038/nrclinonc.2013.175. Epub 2013 Sep 24.
7
[Research impulses for personalized cancer therapies].
Aktuelle Urol. 2013 Sep;44(5):349. doi: 10.1055/s-0033-1353705. Epub 2013 Sep 16.
8
Genetic and metabolic hallmarks of clear cell renal cell carcinoma.
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):23-31. doi: 10.1016/j.bbcan.2018.06.003. Epub 2018 Jun 28.
9
MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Int J Mol Sci. 2017 Nov 22;18(11):2495. doi: 10.3390/ijms18112495.
10
What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?
Pharmacogenomics. 2017 Jan;18(1):1-4. doi: 10.2217/pgs-2016-0168. Epub 2016 Dec 14.
引用本文的文献
1
DOK1 facilitates the advancement of ccRCC.
J Cancer. 2024 Oct 14;15(19):6213-6222. doi: 10.7150/jca.104375. eCollection 2024.
2
ISG15 promotes tumor progression via IL6/JAK2/STAT3 signaling pathway in ccRCC.
Clin Exp Med. 2024 Jun 29;24(1):140. doi: 10.1007/s10238-024-01414-z.
3
Prognostic value of neutrophil extracellular trap signature in clear cell renal cell carcinoma.
Front Oncol. 2023 Jul 13;13:1205713. doi: 10.3389/fonc.2023.1205713. eCollection 2023.
4
P4HA3 promotes clear cell renal cell carcinoma progression via the PI3K/AKT/GSK3β pathway.
Med Oncol. 2023 Jan 2;40(2):70. doi: 10.1007/s12032-022-01926-2.
5
Pyroptosis-Related Gene Signature Predicts the Prognosis of ccRCC Using TCGA and Single-Cell RNA Seq Database.
J Healthc Eng. 2022 Oct 30;2022:8224618. doi: 10.1155/2022/8224618. eCollection 2022.
6
Comprehensive analysis of expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma.
Front Mol Biosci. 2022 Sep 16;9:988777. doi: 10.3389/fmolb.2022.988777. eCollection 2022.
7
The Correlation of HK2 Gene Expression with the Occurrence, Immune Cell Infiltration, and Prognosis of Renal Cell Carcinoma.
Dis Markers. 2022 Feb 27;2022:1452861. doi: 10.1155/2022/1452861. eCollection 2022.
8
MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma.
J Cancer. 2021 Jul 6;12(18):5375-5384. doi: 10.7150/jca.52310. eCollection 2021.
9
Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma.
Cancer Cell Int. 2021 Jun 30;21(1):332. doi: 10.1186/s12935-021-02039-y.
10
Silencing of the Gene by Aberrant Promoter Methylation is Associated with a Poor Patient Outcome and Promotes Cell Proliferation and Migration in Clear Cell Renal Cell Carcinoma.
Front Mol Biosci. 2021 Mar 16;8:655126. doi: 10.3389/fmolb.2021.655126. eCollection 2021.
本文引用的文献
1
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.
2
Comprehensive molecular characterization of clear cell renal cell carcinoma.
Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23.
3
Ten years of progress in renal cell carcinoma.
J Natl Compr Canc Netw. 2012 Jun 1;10(6):690-3. doi: 10.6004/jnccn.2012.0071.
4
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
Nature. 2011 Nov 20;481(7381):380-4. doi: 10.1038/nature10602.
5
Reductive carboxylation supports growth in tumour cells with defective mitochondria.
Nature. 2011 Nov 20;481(7381):385-8. doi: 10.1038/nature10642.
6
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.
Cancer Cell. 2011 Oct 18;20(4):524-37. doi: 10.1016/j.ccr.2011.09.006.
7
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024.
8
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Cancer Cell. 2011 Sep 13;20(3):315-27. doi: 10.1016/j.ccr.2011.07.018.
9
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.
10
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
Nature. 2010 Jan 21;463(7279):360-3. doi: 10.1038/nature08672. Epub 2010 Jan 6.
Zotero 插件